Glycoprotein 2 Antibodies in Crohn's Disease

Advances in Clinical Chemistry

Volumn 60, Issue , 2013, Pages 187-208

  Roggenbuck, Dirk ^a,b   Reinhold, Dirk ^c   Werner, Lael ^d   Schierack, Peter ^a   Bogdanos, Dimitrios P ^e   Conrad, Karsten ^f  

^a Lausitz University of Applied Sciences   (Germany)

^b GA GENERIC ASSAYS GMBH   (Germany)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

^d TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^e KING S COLLEGE HOSPITAL   (United Kingdom)

^f DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Autoantigen; Crohn's disease; Inflammatory bowel disease; Zymogen granule membrane glycoprotein GP2

Indexed keywords

EID: 84875097769     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-407681-5.00006-4     Document Type: Chapter

References (107)

1. Shivananda S., Lennard-Jones J., Logan R., Fear N., Price A., Carpenter L., van Blankenstein M. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European collaborative study on inflammatory bowel disease (EC-IBD). Gut 1996, 39:690-697.
2. Logan I., Bowlus C.L. The geoepidemiology of autoimmune intestinal diseases. Autoimmun. Rev. 2010, 9:A372-A378.
3. Stange E.F., Schreiber S., Folsch U.R., von Herbay A., Scholmerich J., Hoffmann J., et al. Diagnostik und Therapie des Morbus Crohn. Z. Gastroenterol. 2003, 41:19-20.
4. Hay J.W., Hay A.R. Inflammatory bowel disease: costs-of-illness. J. Clin. Gastroenterol. 1992, 14:309-317.
5. Lennard-Jones J.E. Classification of inflammatory bowel disease. Scand. J. Gastroenterol. 1989, 170(Suppl.):2-6.
6. Hampe J., Grebe J., Nikolaus S., Solberg C., Croucher P.J.P., Mascheretti S., et al. Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study. Lancet 2002, 359:1661-1665.
7. Baumgart D.C., Sandborn W.J. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007, 369:1641-1657.
8. Bernstein C.N., Blanchard J.F., Kliewer E., Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001, 15:854-862.
9. Baumgart D.C., Carding S.R. Inflammatory bowel disease: cause and immunobiology. Lancet 2007, 369:1627-1640.
10. Cuthbert A.P., Sheila S.A., Muddassar M.M., King K., Hampe J., Croucher P.J.P., et al. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology 2002, 122:867-874.
11. Shanahan F. Antibody 'markers' in Crohn's disease: opportunity or overstatement?. Gut 1997, 40:557-558.
12. Mayet W.J., Press A.G., Hermann E., Moll R., Mann M., Ewe K., Meyer K.H. Antibodies to cytoskeletal proteins in patients with Crohn's disease. Eur. J. Clin. Invest. 1990, 20:516-524.
13. Saxon A., Shanahan F., Landers C., Ganz T., Targan S. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J. Allergy Clin. Immunol. 1990, 86:202-210.
14. Stöcker W., Otte M., Ulrich S., Normann D., Stöcker K., Jantschek G. Autoantiköper gegen exokrines Pankreas und gegen intestinale Becherzellen in der Diagnostik des Morbus Crohn und der Colitis ulcerosa. Dtsch. Med. Wochenschr. 1984, 109:1963-1969.
15. Stöcker W., Otte M., Ulrich S., Normann D., Finkbeiner H., Stöcker K., et al. Autoimmunity to pancreatic juice in Crohn's disease. Results of an autoantibody screening in patients with chronic inflammatory bowel disease. Scand. J. Gastroenterol. 1987, 139:41-52.
16. Goischke E.M., Zilly W. Klinische Bedeutung organspezifischer Antikorper bei Colitis ulcerosa und Morbus Crohn. Z. Gastroenterol. 1992, 30:319-324.
17. Barthet M., Hastier P., Bernard J.P., Bordes G., Frederick J., Allio S., et al. Chronic pancreatitis and inflammatory bowel disease: true or coincidental association?. Am. J. Gastroenterol. 1999, 94:2141-2148.
18. Spiess S.E., Braun M., Vogelsang R.L., Craig R.M. Crohn's disease of the duodenum complicated by pancreatitis and common bile duct obstruction. Am. J. Gastroenterol. 1992, 87:1033-1036.
19. Seibold F., Weber P., Jenss H., Wiedmann K.H. Antibodies to a trypsin sensitive pancreatic antigen in chronic inflammatory bowel disease: specific markers for a subgroup of patients with Crohn's disease. Gut 1991, 32:1192-1197.
20. Fricke H., Birkhofer A., Folwaczny C., Meister W., Scriba P.C. Characterization of antigens from the human exocrine pancreatic tissue (Pag) relevant as target antigens for autoantibodies in Crohn's disease. Eur. J. Clin. Invest. 1999, 29:41-45.
21. Koutsoumpas A., Polymeros D., Tsiamoulos Z., Smyk D., Karamanolis G., Triantafyllou K., et al. Peculiar antibody reactivity to human connexin 37 and its microbial mimics in patients with Crohn's disease. J. Crohns Colitis 2011, 5:101-109.
22. Vermeulen N., Op de Beeck K., Vermeire S., Van S.K., Michiels G., Ballet V., et al. Identification of a novel autoantigen in inflammatory bowel disease by protein microarray. Inflamm. Bowel Dis. 2011, 17:1291-1300.
23. Saito H., Fukuda Y., Katsuragi K., Tanaka M., Satomi M., Shimoyama T., et al. Isolation of peptides useful for differential diagnosis of Crohn's disease and ulcerative colitis. Gut 2003, 52:535-540.
24. Bogdanos D.P., Rigopoulou E.I., Smyk D.S., Roggenbuck D., Reinhold D., Forbes A., et al. Diagnostic value, clinical utility and pathogenic significance of reactivity to the molecular targets of Crohn's disease specific-pancreatic autoantibodies. Autoimmun. Rev. 2011, 11:143-148.
25. K. Conrad, G. Hausdorf, E. Feist, D. Reinhold, P.R. Jungblut, T. Porstmann, M. Laass, J. Henker, D. Roggenbuck, Identification of GP2 as the major autoantigen of pancreatic autoantibodies, Report on the 6th Congress on Autoimmunity, Porto, Portugal, A1356, 2008.
26. W. Stöcker, M.O. Glocker, C. Probst, B. Teegen, A. Friedrich, S. Sokolowski, L. Komorowski, Identification of two different proteoglycans from exocrine pancreas as the long sought after autoantigens in Crohn's disease: CUZD1 and GP2, Report on the 6th Congress on Autoimmunity, Porto, Portugal, A1177, 2008.
27. Roggenbuck D., Hausdorf G., Martinez-Gamboa L., Reinhold D., Buttner T., Jungblut P.R., et al. Identification of GP2, the major zymogen granule membrane glycoprotein, as the autoantigen of pancreatic antibodies in Crohn's disease. Gut 2009, 58:1620-1628.
28. Stöcker W., Teegen B., Probst C., Aulinger-Stöcker K., Ludwig D., Glocker M.O., Komorowski L. CUZD1 and GP2 are the exocrine pancreas autoantigens in Crohn's disease. From Pathogenesis to Therapy of Autoimmune Disease 2009, 463-473. Pabst Science Publishers, Lengerich. K. Conrad, E.K.L. Chan, M.J. Fritzler, R.-L. Humbel, P.V. Landenberg, Y. Shoenfeld (Eds.).
29. Seibold F., Mörk H., Tanza S., Müller A., Holzhüter C., Weber P., Scheurlen M. Pancreatic autoantibodies in Crohn's disease: a family study. Gut 1997, 40:481-484.
30. Joossens S., Vermeire S., Van S.K., Godefridis G., Claessens G., Pierik M., et al. Pancreatic autoantibodies in inflammatory bowel disease. Inflamm. Bowel Dis. 2004, 10:771-777.
31. Rindler M.J., Hoops T.C. The pancreatic membrane protein GP-2 localizes specifically to secretory granules and is shed into the pancreatic juice as a protein aggregate. Eur. J. Cell Biol. 1990, 53:154-163.
32. Roggenbuck D., Reinhold D., Wex T., Goihl A., von Arnim U., Malfertheiner P., et al. Autoantibodies to GP2, the major zymogen granule membrane glycoprotein, are new markers in Crohn's disease. Clin. Chim. Acta 2011, 412:718-724.
33. Leong C.T., Ong C.K., Tay S.K., Huynh H. Silencing expression of UO-44 (CUZD1) using small interfering RNA sensitizes human ovarian cancer cells to cisplatin in vitro. Oncogene 2007, 26:870-880.
34. Leong C.T., Ng C.Y., Ong C.K., Ng C.P., Ma Z.S., Nguyen T.H., et al. Molecular cloning, characterization and isolation of novel spliced variants of the human ortholog of a rat estrogen-regulated membrane-associated protein, UO-44. Oncogene 2004, 23:5707-5718.
35. Hase K., Kawano K., Nochi T., Pontes G.S., Fukuda S., Ebisawa M., et al. Uptake through glycoprotein 2 of FimH(+) bacteria by M cells initiates mucosal immune response. Nature 2009, 462:226-230.
36. Ohno H., Hase K. Glycoprotein 2 (GP2): grabbing the FimH bacteria into M cells for mucosal immunity. Gut Microbes 2010, 1:407-410.
37. Terahara K., Yoshida M., Igarashi O., Nochi T., Pontes G.S., Hase K., et al. Comprehensive gene expression profiling of Peyer's patch M cells, villous M-like cells, and intestinal epithelial cells. J. Immunol. 2008, 180:7840-7846.
38. Roggenbuck D., Hausdorf G., Martinez-Gamboa L., Reinhold D., Büttner T., Büning C., et al. The zymogen granule glycoprotein GP2 is a major autoantigen of pancreatic antibodies-relevance in diagnostics and pathogenesis of Crohn's disease. From Pathogenesis to Therapy of Autoimmune Diseases 2009, 449-462. Pabst Science Publishers, Lengerich. K. Conrad, E.K.L. Chan, M.J. Fritzler, R.-L. Humbel, P.V. Landenberg, Y. Shoenfeld (Eds.).
39. Richter W., Shi Y., Baekkeskov S. Autoreactive epitopes defined by diabetes-associated human monoclonal antibodies are localized in the middle and C-terminal domains of the smaller form of glutamate decarboxylase. Proc. Natl. Acad. Sci. U.S.A. 1993, 90:2832-2836.
40. Hoops T.C., Ivanov I., Cui Z., Colomer-Gould V., Rindler M.J. Incorporation of the pancreatic membrane protein GP-2 into secretory granules in exocrine but not endocrine cells. J. Biol. Chem. 1993, 268:25694-25705.
41. Ronzio R.A., Kronquist K.E., Lewis D.S., MacDonald R.J., Mohrlok S.H., O'Donnell J.J. Glycoprotein synthesis in the adult rat pancreas. IV. Subcellular distribution of membrane glycoproteins. Biochim. Biophys. Acta 1978, 508:65-84.
42. Havinga J.R., Strous G.J., Poort C. Biosynthesis of the major glycoprotein associated with zymogen-granule membranes in the pancreas. Eur. J. Biochem. 1983, 133:449-454.
43. LeBel D., Beattie M. The major protein of pancreatic zymogen granule membranes (GP-2) is anchored via covalent bonds to phosphatidylinositol. Biochem. Biophys. Res. Commun. 1988, 154:818-823.
44. Fukuoka S., Freedman S.D., Scheele G.A. A single gene encodes membrane-bound and free forms of GP-2, the major glycoprotein in pancreatic secretory (zymogen) granule membranes. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:2898-2902.
45. Fukuoka S.I., Suzuki M., Okabayashi K., Takahashi E. Assignment of pancreatic zymogen granule membrane protein GP2 (GP2) to human chromosome band 9q21.11 to q21.2 by in situ hybridization. Cytogenet. Cell Genet. 1997, 79(3-4):231-232.
46. Fritz B.A., Poppel C.S., Fei M.W., Lowe A.W. Processing of the major pancreatic zymogen granule membrane protein, GP2. Pancreas 2002, 24:336-343.
47. Pennica D., Kohr W.J., Kuang W.-J., Glaister D., Aggarwal B.B., Chen E.Y., Goeddel D.V. Identification of human uromodulin as the Tamm-Horsfall urinary glycoprotein. Science 1987, 236:83-88.
48. Fukuoka S., Freedman S.D., Yu H., Sukhatme V.P., Scheele G.A. GP-2/THP gene family encodes self-binding glycosylphosphatidylinositol-anchored proteins in apical secretory compartments of pancreas and kidney. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:1189-1193.
49. Rindler M.J., Naik S.S., Naik L., Hoops T.C., Peraldi M.N. Uromodulin (Tamm-Horsfall glycoprotein/uromucoid) is a phosphatidylinositol-linked membrane protein. J. Biol. Chem. 1990, 265:20784-20789.
50. Yang H., Wu C., Zhao S., Gui J. Identification and characterization of D8C, a novel domain present in liver-specific LZP, uromodulin and glycoprotein 2, mutated in familial juvenile hyperuricaemic nephropathy. FEBS Lett. 2004, 578:236-238.
51. Shen H.L., Xu Z.G., Huang L.Y., Liu D., Lin D.H., Cao J.B., et al. Liver-specific ZP domain-containing protein (LZP) as a new partner of Tamm-Horsfall protein harbors on renal tubules. Mol. Cell. Biochem. 2009, 321:73-83.
52. Nguyen H.T.T., Amine A.B., Lafitte D., Waheed A.A., Nicoletti C., Villard C., et al. Proteomic characterization of lipid rafts markers from the rat intestinal brush border. Biochem. Biophys. Res. Commun. 2006, 342:236-244.
53. Schmidt K., Dartsch H., Linder D., Kern H.F., Kleene R. A submembranous matrix of proteoglycans on zymogen granule membranes is involved in granule formation in rat pancreatic acinar cells. J. Cell Sci. 2000, 113:2233-2242.
54. Kalus I., Hodel A., Koch A., Kleene R., Edwardson J.M., Schrader M. Interaction of syncollin with GP-2, the major membrane protein of pancreatic zymogen granules, and association with lipid microdomains. Biochem. J. 2002, 362:433-442.
55. Colomer V., Lal K., Hoops T.C., Rindler M.J. Exocrine granule specific packaging signals are present in the polypeptide moiety of the pancreatic granule membrane protein GP2 and in amylase: implications for protein targeting to secretory granules. EMBO J. 1994, 13:3711-3719.
56. Yu S., Michie S.A., Lowe A.W. Absence of the major zymogen granule membrane protein, GP2, does not affect pancreatic morphology or secretion. J. Biol. Chem. 2004, 279:50274-50279.
57. Kobayashi K., Yanagihara K., Ishiguro K., Fukuoka S. GP2/THP gene family of self-binding, GPI-anchored proteins forms a cluster at chromosome 7F1 region in mouse genome. Biochem. Biophys. Res. Commun. 2004, 322:659-664.
58. Dou W., Thompson-Jaeger S., Laulederkind S.J., Becker J.W., Montgomery J., Ruiz-Bustos E., et al. Defective expression of Tamm-Horsfall protein/uromodulin in COX-2-deficient mice increases their susceptibility to urinary tract infections. Am. J. Physiol. Renal Physiol. 2005, 289:F49-F60.
59. Pak J., Pu Y., Zhang Z.T., Hasty D.L., Wu X.R. Tamm-Horsfall protein binds to type 1 fimbriated Escherichia coli and prevents E. coli from binding to uroplakin Ia and Ib receptors. J. Biol. Chem. 2001, 276:9924-9930.
60. Yu S., Lowe A.W. The pancreatic zymogen granule membrane protein, GP2, binds Escherichia coli Type 1 fimbriae. BMC Gastroenterol. 2009, 9:58.
61. Säemann M.D., Weichhart T., Zeyda M., Staffler G., Schunn M., Stuhlmeier K.M., et al. Tamm-Horsfall glycoprotein links innate immune cell activation with adaptive immunity via a Toll-like receptor-4-dependent mechanism. J. Clin. Invest. 2005, 115:468-475.
62. Holzl M.A., Hofer J., Kovarik J.J., Roggenbuck D., Reinhold D., Goihl A., et al. The zymogen granule protein 2 (GP2) binds to scavenger receptor expressed on endothelial cells I (SREC-I). Cell. Immunol. 2011, 267:88-93.
63. Werner L., Paclik D., Fritz C., Reinhold D., Roggenbuck D., Sturm A. Identification of pancreatic Glycoprotein 2 as an endogenous immunomodulator of innate and adaptive immune responses. J. Immunol. 2012, 189:2774-2783.
64. Soderholm J.D., Olaison G., Peterson K.H., Franzen L.E., Lindmark T., Wiren M., et al. Augmented increase in tight junction permeability by luminal stimuli in the non-inflamed ileum of Crohn's disease. Gut 2002, 50:307-313.
65. Cario E., Podolsky D.K. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect. Immun. 2000, 68:7010-7017.
66. Franchimont D., Vermeire S., El H.H., Pierik M., Van S.K., Gustot T., et al. Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut 2004, 53:987-992.
67. Baumgart D.C., Metzke D., Schmitz J., Scheffold A., Sturm A., Wiedenmann B., Dignass A.U. Patients with active inflammatory bowel disease lack immature peripheral blood plasmacytoid and myeloid dendritic cells. Gut 2005, 54:228-236.
68. Ina K., Itoh J., Fukushima K., Kusugami K., Yamaguchi T., Kyokane K., et al. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. J. Immunol. 1999, 163:1081-1090.
69. Gullberg E., Soderholm J.D. Peyer's patches and M cells as potential sites of the inflammatory onset in Crohn's disease. Ann. N. Y. Acad. Sci. 2006, 1072:218-232.
70. Olaison G., Smedh K., Sjodahl R. Recurrence of Crohn's disease in the neo-terminal ileum and colonic factors. Lancet 1991, 338:1401.
71. Van Kruiningen H.J., West A.B., Freda B.J., Holmes K.A. Distribution of Peyer's patches in the distal ileum. Inflamm. Bowel Dis. 2002, 8:180-185.
72. Pavlidis P., Mytilinaiou M.G., Roggenbuck D., Conrad K., Forbes A., Bogdanos D.P. Pancreatic GP2-specific autoantibodies are markers of Crohńs disease. Gut 2011, 60:A212-A213.
73. Bogdanos D.P., Roggenbuck D., Reinhold D., Wex T., Pavlidis P., von Arnim U., et al. Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn's disease. BMC Gastroenterol. 2012, 12:102.
74. Hausdorf G., Roggenbuck D., Feist E., Buttner T., Jungblut P.R., Conrad K., et al. Autoantibodies to asialoglycoprotein receptor (ASGPR) measured by a novel ELISA-revival of a disease-activity marker in autoimmune hepatitis. Clin. Chim. Acta 2009, 408:19-24.
75. Rigopoulou E.I., Roggenbuck D., Smyk D.S., Liaskos C., Mytilinaiou M.G., Feist E., et al. Asialoglycoprotein receptor (ASGPR) as target autoantigen in liver autoimmunity: lost and found. Autoimmun. Rev. 2012, 11:143-148.
76. Darfeuille-Michaud A., Boudeau J., Bulois P., Neut C., Glasser A.L., Barnich N., et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 2004, 127:412-421.
77. Garcia Rodriguez L.A., Ruigomez A., Panes J. Acute gastroenteritis is followed by an increased risk of inflammatory bowel disease. Gastroenterology 2006, 130:1588-1594.
78. Pavlidis P., Forbes A., Bogdanos D.P. Antibodies to glycoprotein 2 (GP2) in patients with inflammatory bowel diseases from UK. Clin. Chim. Acta 2011, 412:1163-1164.
79. Bonaci-Nikolic B., Spuran M., Andrejevic S., Nikolic M. Autoantibodies to GP2, the major zymogen granule membrane glycoprotein, in patients with gluten-sensitive enteropathy: a possible serological trap. Clin. Chim. Acta 2012, 413:822-823.
80. Roggenbuck D., Bogdanos D.P., Reinhold D., Conrad K. Antibodies to the zymogen granule membrane glycoprotein 2 (GP2): serological markers for Crohn's disease. Clin. Lab. Int. 2011, 35:16-19.
81. Op de Beeck K., Vermeire S., Rutgeerts P., Bossuyt X. Antibodies to GP2, the major zymogen granule membrane glycoprotein, in inflammatory bowel diseases. Gut 2010, 61:162-164.
82. Kim K.P., Kim M.H., Song M.H., Lee S.S., Seo D.W., Lee S.K. Autoimmune chronic pancreatitis. Am. J. Gastroenterol. 2004, 99:1605-1616.
83. Lowe A.W., Luthen R.E., Wong S., Grendell J.H. The level of the zymogen granule protein GP2 is elevated in a rat model for acute pancreatitis. Gastroenterology 1994, 107:1819-1827.
84. Hao Y., Wang J., Feng N., Lowe A.W. Determination of plasma glycoprotein 2 levels in patients with pancreatic disease. Arch. Pathol. Lab. Med. 2004, 128:668-674.
85. Freedman S.D., Sakamoto K., Venu R.P. GP2, the homologue to the renal cast protein uromodulin, is a major component of intraductal plugs in chronic pancreatitis. J. Clin. Invest. 1993, 92:83-90.
86. McQueen E.G., Engel G.B. Factors determining the aggregation of urinary mucoprotein. J. Clin. Pathol. 1966, 19:392-396.
87. Ying W.Z., Sanders P.W. Mapping the binding domain of immunoglobulin light chains for Tamm-Horsfall protein. Am. J. Pathol. 2001, 158:1859-1866.
88. Colombel J.F., Watson A.J., Neurath M.F. The 10 remaining mysteries of inflammatory bowel disease. Gut 2008, 57:429-433.
89. Roggenbuck D., Reinhold D., Wex T., von Arnim U., Malfertheiner P., Sturm A., et al. Authors' response: antibodies to GP2, the major zymogen granule membrane glycoprotein, are specific for Crohn's disease and may reflect treatment response. Gut 2012, 61:164-165.
90. Price A. Overlap in the spectrum of non-specific inflammatory bowel disease-́colitis indeterminaté. J. Biol. Chem. 1978, 265:567-577.
91. Conrad K., Schmechta H., Klafki A., Lobeck G., Uhlig H.H., Gerdi S., Henker J. Serological differentiation of inflammatory bowel diseases. Eur. J. Gastroenterol. Hepatol. 2002, 14:129-135.
92. Bossuyt X. Serologic markers in inflammatory bowel disease. Clin. Chem. 2006, 52:171-181.
93. Guindi M., Riddell R.H. Indeterminate colitis. J. Clin. Pathol. 2004, 57:1233-1244.
94. Wells A.D., McMillan I., Price A.B., Ritchie J.K., Nicholls R.J. Natural history of indeterminate colitis. Br. J. Surg. 1991, 78:179-181.
95. Giaffer M.H., Clark A., Holdsworth C.D. Antibodies to Saccharomyces cerevisiae in patients with Crohn's disease and their possible pathogenic importance. Gut 1992, 33:1071-1075.
96. Barnes R.M., Allan S., Taylor-Robinson C.H., Finn R., Johnson P.M. Serum antibodies reactive with Saccharomyces cerevisiae in inflammatory bowel disease: is IgA antibody a marker for Crohn's disease?. Int. Arch. Allergy Appl. Immunol. 1990, 92:9-15.
97. Ferrante M., Henckaerts L., Joossens M., Pierik M., Joossens S., Dotan N., et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 2007, 56:1394-1403.
98. Rieder F., Schleder S., Wolf A., Dirmeier A., Strauch U., Obermeier F., et al. Serum anti-glycan antibodies predict complicated Crohn's disease behavior: a cohort study. Inflamm. Bowel Dis. 2010, 16:1367-1375.
99. Rieder F., Schleder S., Wolf A., Dirmeier A., Strauch U., Obermeier F., et al. Association of the novel serologic anti-glycan antibodies anti-laminarin and anti-chitin with complicated Crohn's disease behavior. Inflamm. Bowel Dis. 2010, 16:263-274.
100. Rieder F., Lopez R., Franke A., Wolf A., Schleder S., Dirmeier A., et al. Characterization of changes in serum anti-glycan antibodies in Crohn's disease-a longitudinal analysis. PLoS One 2011, 6:e18172.
101. Le Q., Melmed G., Dubinsky M., McGovern D., Vasiliauskas E.A., Murrell Z., et al. Surgical outcome of ileal pouch-anal anastomosis when used intentionally for well-defined Crohn's disease. Inflamm. Bowel Dis. 2013, 19:30-36.
102. Papp M., Altorjay I., Dotan N., Palatka K., Foldi I., Tumpek J., et al. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort. Am. J. Gastroenterol. 2008, 103:665-681.
103. Dotan I. New serologic markers for inflammatory bowel disease diagnosis. Dig. Dis. 2010, 28:418-423.
104. Tyler A.D., Milgrom R., Xu W., Stempak J.M., Steinhart A.H., McLeod R.S., et al. Antimicrobial antibodies are associated with a Crohn's disease-like phenotype after ileal pouch-anal anastomosis. Clin. Gastroenterol. Hepatol. 2012, 10:507-512.
105. Conrad K., Roggenbuck D., Reinhold D., Dorner T. Profiling of rheumatoid arthritis associated autoantibodies. Autoimmun. Rev. 2009, 9:431-435.
106. Egerer K., Roggenbuck D., Buettner T., Lehmann B., Kohn A., von Landenberg P., et al. Single-step autoantibody profiling in antiphospholipid syndrome using a multi-line dot assay. Arthritis Res. Ther. 2011, 13:R118.
107. Roggenbuck D., Egerer K., Feist E., Burmester G.R., Dorner T. Antiphospholipid antibody profiling-association with the clinical phenotype in APS?. Arthritis Rheum. 2012, 64:2807-2808.